Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 22469974 
Griner EM, Churchill ME, Brautigan DL, Theodorescu D (2013) PKCĪ± phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity. Oncogene 32, 1010-7 22469974
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S20-p - RhoGDI beta (human)
Orthologous residues
RhoGDI beta (human): S20‑p, RhoGDI beta (mouse): S19‑p, RhoGDI beta (rat): S19‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human

S31-p - RhoGDI beta (human)
Orthologous residues
RhoGDI beta (human): S31‑p, RhoGDI beta (mouse): S30‑p, RhoGDI beta (rat): S30‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCA (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
GF109203X phorbol ester inhibit treatment-induced increase
Go 6976 phorbol ester inhibit treatment-induced increase
siRNA phorbol ester inhibit treatment-induced increase PKCA siRNA
Downstream Regulation
 Effect of modification (function):  activity, inhibited, molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
RAC1 (human) Disrupts intracellular localization co-immunoprecipitation
 Comments:  impaired GDI2 function


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.